유럽 연합 - 포르투갈어 - EMA (European Medicines Agency)

secura bio limited - duvelisib - leukemia, lymphocytic, chronic, b-cell; lymphoma, follicular - agentes antineoplásicos - copiktra monotherapy is indicated for the treatment of adult patients with: relapsed or refractory chronic lymphocytic leukaemia (cll) after at least two prior therapies.  follicular lymphoma (fl) that is refractory to at least two prior  systemic therapies.

유럽 연합 - 포르투갈어 - EMA (European Medicines Agency)

gedeon richter plc. - relugolix, norethisterone acetate, estradiol hemihydrate - leiomioma - hormonas e análises pituitárias e hipotalâmicas - ryeqo is indicated in adult women of reproductive age for:- treatment of moderate to severe symptoms of uterine fibroids,- symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.

유럽 연합 - 포르투갈어 - EMA (European Medicines Agency)

vifor fresenius medical care renal pharma france - avacopan - microscopic polyangiitis; wegener granulomatosis - imunossupressores - tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (gpa) or microscopic polyangiitis (mpa).

유럽 연합 - 포르투갈어 - EMA (European Medicines Agency)

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - agentes antineoplásicos - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

유럽 연합 - 포르투갈어 - EMA (European Medicines Agency)

pfizer europe ma eeig  - rimegepant - transtornos da enxaqueca - antimigraine preparations, calcitonin gene-related peptide (cgrp) antagonists - vydura is indicated for theacute treatment of migraine with or without aura in adults;preventative treatment of episodic migraine in adults who have at least 4 migraine attacks per month.

포르투갈 - 포르투갈어 - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

merck, s.a. - glibenclamida + metformina - comprimido revestido por película - 2.5 mg + 500 mg - metformina, cloridrato 500 mg ; glibenclamida 2.5 mg - metformin and sulfonylureas - n/a - duração do tratamento: longa duração

포르투갈 - 포르투갈어 - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

teva pharma - produtos farmacêuticos, lda. - ciclosporina - cápsula mole - 50 mg - ciclosporina 50 mg - ciclosporin - genérico - duração do tratamento: longa duração

포르투갈 - 포르투갈어 - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

teva pharma - produtos farmacêuticos, lda. - ciclosporina - cápsula mole - 50 mg - ciclosporina 50 mg - ciclosporin - genérico - duração do tratamento: longa duração

포르투갈 - 포르투갈어 - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

zentiva portugal, lda. - darunavir - comprimido revestido por película - 600 mg - darunavir 600 mg - darunavir - genérico - duração do tratamento: longa duração

포르투갈 - 포르투갈어 - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

generis farmacêutica, s.a. - ciclosporina - cápsula mole - 100 mg - ciclosporina 100 mg - ciclosporin - genérico - duração do tratamento: longa duração